Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions
The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have bee...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2010/516768 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841524826569703424 |
---|---|
author | Shigeo Koido Sadamu Homma Eiichi Hara Yoshihisa Namiki Akitaka Takahara Hideo Komita Eijiro Nagasaki Masaki Ito Toshifumi Ohkusa Jianlin Gong Hisao Tajiri |
author_facet | Shigeo Koido Sadamu Homma Eiichi Hara Yoshihisa Namiki Akitaka Takahara Hideo Komita Eijiro Nagasaki Masaki Ito Toshifumi Ohkusa Jianlin Gong Hisao Tajiri |
author_sort | Shigeo Koido |
collection | DOAJ |
description | The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment. |
format | Article |
id | doaj-art-9bcbc88057804adab53162508cf3d31a |
institution | Kabale University |
issn | 1740-2522 1740-2530 |
language | English |
publishDate | 2010-01-01 |
publisher | Wiley |
record_format | Article |
series | Clinical and Developmental Immunology |
spelling | doaj-art-9bcbc88057804adab53162508cf3d31a2025-02-03T05:47:17ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/516768516768Regulation of Tumor Immunity by Tumor/Dendritic Cell FusionsShigeo Koido0Sadamu Homma1Eiichi Hara2Yoshihisa Namiki3Akitaka Takahara4Hideo Komita5Eijiro Nagasaki6Masaki Ito7Toshifumi Ohkusa8Jianlin Gong9Hisao Tajiri10Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanDepartment of Oncology, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo 105-8461, JapanSaitama Cancer Center Research Institute for Clinical Oncology, Saitama 362-0806, JapanInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo 277-8567, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo 277-8567, JapanInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo 277-8567, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanDepartment of Medicine, Boston University School of Medicine, Boston, MA 02118, USADivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanThe goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.http://dx.doi.org/10.1155/2010/516768 |
spellingShingle | Shigeo Koido Sadamu Homma Eiichi Hara Yoshihisa Namiki Akitaka Takahara Hideo Komita Eijiro Nagasaki Masaki Ito Toshifumi Ohkusa Jianlin Gong Hisao Tajiri Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions Clinical and Developmental Immunology |
title | Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions |
title_full | Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions |
title_fullStr | Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions |
title_full_unstemmed | Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions |
title_short | Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions |
title_sort | regulation of tumor immunity by tumor dendritic cell fusions |
url | http://dx.doi.org/10.1155/2010/516768 |
work_keys_str_mv | AT shigeokoido regulationoftumorimmunitybytumordendriticcellfusions AT sadamuhomma regulationoftumorimmunitybytumordendriticcellfusions AT eiichihara regulationoftumorimmunitybytumordendriticcellfusions AT yoshihisanamiki regulationoftumorimmunitybytumordendriticcellfusions AT akitakatakahara regulationoftumorimmunitybytumordendriticcellfusions AT hideokomita regulationoftumorimmunitybytumordendriticcellfusions AT eijironagasaki regulationoftumorimmunitybytumordendriticcellfusions AT masakiito regulationoftumorimmunitybytumordendriticcellfusions AT toshifumiohkusa regulationoftumorimmunitybytumordendriticcellfusions AT jianlingong regulationoftumorimmunitybytumordendriticcellfusions AT hisaotajiri regulationoftumorimmunitybytumordendriticcellfusions |